Evaluation – Jack Feeny Reviews http://jackfeenyreviews.com/ Fri, 14 Jan 2022 06:40:57 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://jackfeenyreviews.com/wp-content/uploads/2021/06/icon-1-150x150.png Evaluation – Jack Feeny Reviews http://jackfeenyreviews.com/ 32 32 Research Assessment Officer Job with SWINBURNE UNIVERSITY OF TECHNOLOGY https://jackfeenyreviews.com/research-assessment-officer-job-with-swinburne-university-of-technology/ Fri, 14 Jan 2022 04:44:06 +0000 https://jackfeenyreviews.com/research-assessment-officer-job-with-swinburne-university-of-technology/ Swinburne Research Full-time term position until February 2024 at our Hawthorn campus HEW 7: $90,692 – $97,797 plus 17% super About the job We are looking for a Research Assessment Officer to join us to be responsible for a range of duties and tasks required to plan and prepare for the University’s submission to the […]]]>
  • Swinburne Research
  • Full-time term position until February 2024 at our Hawthorn campus
  • HEW 7: $90,692 – $97,797 plus 17% super

About the job

We are looking for a Research Assessment Officer to join us to be responsible for a range of duties and tasks required to plan and prepare for the University’s submission to the Excellence in Research for Australia (ERA) initiative expected in 2023, and Engagement and Impact (EI) submission expected in 2024.

As the Technical Lead and under the overall direction of the Research Analytics Services Manager, you will work closely with the Research Analytics Services team, the Library and the ERA and EI Discipline Managers to perform the key technical tasks of projects and ensure that tasks related to research and data management, as well as modeling and bid optimization are executed efficiently and accurately.

Your role will require you to interpret and apply policies, guidelines and technical specifications to develop systems and manage data collections required for the University’s ERA submission, adapting existing systems or processes as necessary. You will extract data from existing systems and provide solutions where data needs to be extracted, and be responsible for data manipulation and modeling, working with senior academic staff to ensure data is coded appropriately and that the other technical requirements of the bid are met. As a Research Assessment Officer, you will need to present complex data clearly to inform key stakeholder decisions, and provide analysis, updates and guidance on submission to ensure optimal outcome for the University.

To be successful in this role, you must have strong technical abilities and be able to refer to relevant specifications, guidelines, strategies and processes to inform your work. The role requires a high level of organization and attention to detail. You are expected to anticipate technical issues and work towards common sense solutions. Discretion as to the processing of certain information is also an important element. Time management skills and the ability to prioritize competing demands are essential.

About Swinburne University of Technology

Swinburne is a young university with a long history. As a dual-sector university of technology, born out of a technical college, we are proud of Swinburne’s technology DNA and our national and global reputation. Our contribution to technology, entrepreneurship, innovation and STEM disciplines, as well as our track record of meaningful industry and community engagement, are natural manifestations of the legacy initiated by the vision of our founders George and Ethel Swinburne in 1902. We offer postgraduate, undergraduate, professional education and online education to provide students with a variety of work-relevant pathways.

About you

To be suitable for the role, you will have:

  • Demonstrated experience in data management and manipulation, including the ability to write advanced SQL queries and PHP scripts to extract and manipulate data from source systems and reporting platforms.
  • Proven analytical and problem-solving skills, ideally in relation to information systems and the interpretation of reporting guidelines and technical specifications.
  • Demonstrated ability to produce high quality reports and visualizations and clearly present complex information for distribution to a range of stakeholders.
  • Knowledge of and experience in analyzing large, complex datasets and demonstrated ability to provide analysis and feedback on issues.

A full list of selection criteria is available in the job description.

Advantages

To find out more about the wide range of benefits available to Swinburne employees, please visit Careers at Swinburne and see the ‘Benefits’ section.

How to apply and more information

To view the job description or to begin an application, please click apply or “get started” and submit a resume, cover letter, and response to key selection criteria as outlined in the job description.

For further information on this position, contact Michelle Vincent – Manager Research Analytics Services – mvincent@swin.edu.au

If you are having technical difficulties with your application, please contact the recruitment team on staffrecruitment@swin.edu.au

Diversity and Inclusion

Equity and diversity are integral to achieving our 2025 vision of bringing people and technology together to build a better world. Swinburne is a large, culturally diverse organization and we pride ourselves on our commitment to equity and inclusion through key initiatives such as:

  • Reconciliation Action Plan
  • Cultural Diversity Charter
  • Action Plan for Gender Equity in Science in Australia (SAGE)
  • Swinburne’s LGBTIQA+ Pride, Gender Equality, Accessibility and Intergenerational Inclusion Strategies

For more information on all of our initiatives, visit our Equity and Diversity website. We welcome and encourage applicants from diverse backgrounds to apply.

Help and support

We are committed to making the recruitment process fair and equitable for all of our applicants. If you have specific accessibility or support needs, please contact Maree Norden, Diversity and Inclusion Manager at inclusion@swin.edu.au. For help or questions regarding Aboriginal and Torres Strait Islander employment, please contact Timothy Werner at DeadlyCareers@swin.edu.au

Swinburne offers flexible work options, time off and parental/caregiver policies to support work-life balance.

Victoria’s Minister of Health orders require all workers at Swinburne to be fully vaccinated against COVID-19, unless they are an excepted person as defined by the Compulsory Vaccination Order 2021 COVID-19 pandemic (specified workers) (#1). All applicants must therefore be able to comply with this requirement.

Applications closed at 5 p.m., Friday, January 28, 2022

(Agency inquiries will not be accepted for this position)

]]>
Tabor Bombing Suspect Awaits Skills Assessment | Community https://jackfeenyreviews.com/tabor-bombing-suspect-awaits-skills-assessment-community/ Wed, 12 Jan 2022 04:03:00 +0000 https://jackfeenyreviews.com/tabor-bombing-suspect-awaits-skills-assessment-community/ TYNDALL – The case of a Tabor man suspected of a bombing last summer remains open after a status hearing on Tuesday. Joseph Thomas Hansen is currently being held in Bon Homme County Jail while his lawyer, Luci Youngberg, arranges a mental assessment for his client. Youngberg filed a motion on Tuesday asking circuit judge […]]]>

TYNDALL – The case of a Tabor man suspected of a bombing last summer remains open after a status hearing on Tuesday.

Joseph Thomas Hansen is currently being held in Bon Homme County Jail while his lawyer, Luci Youngberg, arranges a mental assessment for his client.

Youngberg filed a motion on Tuesday asking circuit judge Cheryle Gering to extend Hansen’s skills assessment deadline. In the motion, Youngberg said that all necessary records had been received by clinical psychologist Taryn Van Gilder-Pierce as of Jan.6, but that due to staff illness with COVID and other illnesses, the assessment no could not be completed in the allotted time.

Gering ordered the deadline for the skills assessment to be extended to February 4 and scheduled a status hearing for 11 a.m. on February 11.

Hansen came to the attention of authorities last August when he was found unconscious in his driveway with thermal burns after his home in Tabor exploded.

A search of the structure uncovered two fully assembled homemade bombs and nine empty plugged pipes next to a fuse and fireworks.

Hansen later told police that he planned to make 12 homemade bombs using the powder from the fireworks, but had only completed three to five homemade bombs when one of them hit. exploded. He also told investigators he had gasoline and a propane cylinder in his room.

When Hansen was 18 and lived in Claire City, he was convicted of bombing. At the time, he was convicted of possession of ammunition and fireworks as part of a plan to blow up the Sisseton High School, which he attended.

Hansen served 10 years on these charges. After his release he moved to Tabor.

Pending assessment of his mental capacity, Hansen, now 29, could face two counts of selling, transporting or possessing a destructive device and nine counts of unauthorized possession. of substances with the intention of manufacturing a destructive device.

Hansen was viewed as a potential danger to the community when he was arrested in August and is being held on $ 250,000 cash-only bond.

]]>
Khondrion Completes Enrollment in Phase IIb KHENERGYZE Trial Evaluating Sonlicromanol in Adult Patients with MELAS Spectrum Disorders https://jackfeenyreviews.com/khondrion-completes-enrollment-in-phase-iib-khenergyze-trial-evaluating-sonlicromanol-in-adult-patients-with-melas-spectrum-disorders/ Mon, 10 Jan 2022 07:09:15 +0000 https://jackfeenyreviews.com/khondrion-completes-enrollment-in-phase-iib-khenergyze-trial-evaluating-sonlicromanol-in-adult-patients-with-melas-spectrum-disorders/ Khondrion complete registration in KHENERGYZE Phase IIb test assess sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, THE NETHERLANDS – JANUARY 10, 2022: Khondrion, a clinical-stage biopharmaceutical company that discovers and develops therapies targeting primary mitochondrial diseases, today announced that the latest patient has received a dose of sonlicromanol as part of the ‘KHENERGYZE […]]]>

Khondrion complete registration in KHENERGYZE Phase IIb test assess sonlicromanol in adult patients with MELAS spectrum disorders

NIJMEGEN, THE NETHERLANDS – JANUARY 10, 2022: Khondrion, a clinical-stage biopharmaceutical company that discovers and develops therapies targeting primary mitochondrial diseases, today announced that the latest patient has received a dose of sonlicromanol as part of the ‘KHENERGYZE phase IIb clinical study. Sonlicromanol is the main 100% owned ingredient in Khondrion, developed to treat a range of mitochondrial diseases in children and adults. KHENERGYZE topline data is expected in the third quarter of 2022.

The primary objective of the study is to assess the dose effect of sonlicromanol on the attention domain score of cognitive functioning, as assessed by the Cogstate computerized visual identification test. Cognitive impairment is increasingly recognized in patients with mitochondrial diseases and can have a significant and debilitating impact on many aspects of their lives. The potential of sonlicromanol to counter cognitive decline is supported by preclinical research and the results of a completed Phase IIa study, which showed significant improvement in attention and mood outcomes in patients treated with sonlicromanol compared to placebo.

Khondrion Managing Director Prof Jan Smeitink said: End of registration in our Phase IIb study is an important step and brings us one step closer to providing an urgent and much needed disease modifying therapy for patients with severe and debilitating mitochondrial diseases. I would like to express my gratitude to all patients and their families for their participation in this trial, as well as to the investigators and the broader team, whose dedication has been vital in advancing this important clinical programmme. WWe are looking forward to to receive results of the trial later in the year. ”

Sonlicromanol is a first-class oral small molecule targeting key underlying mechanisms of mitochondrial disease based on its unique triple mode of action: redox modulation to help restore cell metabolism, radical scavenging preventing ferroptotic cell death and inhibition of mPGES-1 resulting in anti-inflammatory effects. In phase I and phase IIa studies, sonlicromanol has shown a good safety and tolerability profile well beyond the target therapeutic doses.

KHENERGYZE is a double-blind, randomized, placebo-controlled, multicenter, three-way crossover study examining cognitive function in adult patients with a specific genetic mutation of DNA in mitochondrial transfer RNA.Leu(UUR) (MT-TL1m.3243A> G). This mutation is responsible for disorders of the MELAS spectrum, in particular MELAS syndromes (mitochondrial encephalomyopathy, lactic acidosis and stroke), MIDD syndromes (diabetes and deafness of maternal origin) and mixed phenotypes.

Sonlicromanol’s development program also includes two other ongoing clinical studies: the open-label KHENEREXT Phase IIb extension study, examining the long-term safety and efficacy of sonlicromanol in adult patients who have completed the KHENERGYZE study, and the KHENERGYC Phase II study in children.

Further details on the KHENERGYZE study are available at clinicaltrials.gov.

– ENDS

Contacts:

Khondrion BV
Teacher. Dr. Jan Smeitink, CEO
Email: info@khondrion.com
Phone: + 31-24-7635000
www.khondrion.com

Strategic Communication Consilium
Mary-Jane Elliott, David Daley, Melissa Gardiner
Email: khondrion@consilium-comms.com
Phone. : +44 20 3709 5700

About Khondrion
Khondrion is a clinical-stage biopharmaceutical company developing therapies for patients with inherited mitochondrial diseases. Based on proprietary science and a deep biological understanding of mitochondrial dysfunction, the company is advancing its lead drug candidate, sonlicromanol, a first-class oral small molecule targeting key underlying mechanisms of mitochondrial disease based on the drug’s unique triple mode of action.

One of the most advanced disease-modifying drug candidates for developing mitochondrial disease, sonlicromanol is currently being tested in a phase IIb trial and a 12-month open-label extension study in adult patients with MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke -like episodes) of spectrum disorders, as well as in a 6-month phase II study in children with genetically confirmed primary mitochondrial diseases and who suffer from motor symptoms. The compound has received orphan drug designations for the treatment of MELAS, Leigh’s disease, and patients with maternal inherited diabetes and deafness (MIDD) in Europe, and for all inherited disorders of the mitochondrial respiratory chain in the States. -United. It has also received a rare pediatric disease designation in the United States for the treatment of MELAS. Sonlicromanol and other compounds from Khondrion’s proprietary library have the potential to be developed for a wide range of diseases and conditions to benefit patients whose daily lives are severely affected by mitochondrial impairment.

For more information, visit www.khondrion.com.

About mitochondrial disease
Mitochondrial disease occurs when the mitochondria, which are present in all cells of the human body and responsible for producing the energy necessary for cells to function, fail. This can lead to a wide range of serious and debilitating illnesses occurring soon after birth or later in life. Signs and symptoms of these may include cognitive problems, learning disabilities, blindness, deafness, heart failure, diabetes, fatigue, exercise intolerance, muscle weakness, and gait problems, and stunted growth. Orphan diseases of the oxidative phosphorylation system such as Leigh’s disease, MELAS spectrum disorders (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes), including MIDD (maternal inherited diabetes and deafness), and Other respiratory chain disorders / oxidative phosphorylation, are all examples of mitochondrial disease. MELAS spectrum disorders are among the most frequently observed primary mitochondrial diseases, in which all patients are characterized by an underlying point mutation (m.3243A> G) in the MTTL1 gene inherited from the mother.


Source link

]]>
Tigers trio named to On3’s Top 100 NIL Ratings list https://jackfeenyreviews.com/tigers-trio-named-to-on3s-top-100-nil-ratings-list/ Sat, 08 Jan 2022 17:45:00 +0000 https://jackfeenyreviews.com/tigers-trio-named-to-on3s-top-100-nil-ratings-list/ The game changed for collegiate athletes on July 1, 2021. It was the day it was announced that they could finally benefit from their name, image and likeness. Prior to this date, athletes could not earn money and maintain their NCAA amateur athlete status. Players like Spencer Rattler have started his own dressing room, we’ve […]]]>

The game changed for collegiate athletes on July 1, 2021. It was the day it was announced that they could finally benefit from their name, image and likeness. Prior to this date, athletes could not earn money and maintain their NCAA amateur athlete status.

Players like Spencer Rattler have started his own dressing room, we’ve seen DJ Uiagalelei in the Dr. Pepper commercials. Even LSU quarterback Myles Brennan jumped into the action as he received a new truck as he would represent the Ford brand of trucks for a local car dealership.

Recently, On3 launched its NIL coverage with the top 100 athletes and what they could win. It was based on their popularity and social media following.

The On3 NIL Appraisal is an index that seeks to establish standard market value for high school and college level athletes. The NIL valuation does not act as a tracker of the value of the NIL transactions that an athlete has entered into to date. Rather, it means the worth of an athlete at a certain point in time.

A trio of LSU Tigers were on the list. Starting at No.49, LSU cornerback Derek Stingley Jr who recently declared himself for the NFL Draft.

Details:

  • NIL On3 Assessment: $ 181,000
  • IG Followers: 151K

Next is quarterback who removed his name from the transfer portal and will return in 2022, Myles Brennan. It arrives at n ° 72.

Details:

  • NIL On3 Assessment: $ 144,000
  • IG Followers: 86K
  • TikTok subscribers: 181
  • Twitter followers: 22K

Finally, we have another quarterback with freshman Garrett Nussmeier. He finished his first season with the Tigers and saw limited action. He ranks as player # 84 on the list.

Details:

  • NIL Rating on On3: $ 128,000
  • IG Followers: 33K
  • TikTok Subscribers: 258K
  • Twitter Followers: 9.3K


Source link

]]>
Web Accessibility Assessment Tools 2021 Market Outlook Analysis by Major Key Players https://jackfeenyreviews.com/web-accessibility-assessment-tools-2021-market-outlook-analysis-by-major-key-players/ Thu, 06 Jan 2022 21:14:16 +0000 https://jackfeenyreviews.com/web-accessibility-assessment-tools-2021-market-outlook-analysis-by-major-key-players/ New Jersey, United States, – The Global Web Accessibility Assessment Tools Market report is one of the most comprehensive and significant addition to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Web Accessibility Assessment Tools market. The market analysts who produced the report […]]]>

New Jersey, United States, – The Global Web Accessibility Assessment Tools Market report is one of the most comprehensive and significant addition to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Web Accessibility Assessment Tools market. The market analysts who produced the report have provided in-depth information on key growth drivers, restraints, challenges, trends, and opportunities to provide a comprehensive analysis of the global Web Accessibility Assessment Tools market. . Market players can use the analysis of market dynamics to plan effective growth strategies and prepare for future challenges in advance.

Each trend in the global Web Accessibility Assessment Tools market is carefully analyzed and studied by market analysts. Market analysts and researchers have performed an in-depth analysis of the global Web Accessibility Assessment Tools Market using research methodologies such as Pestle and Porter’s Five Forces Analysis.

They have provided accurate and reliable market data and helpful recommendations with the aim of helping players get an overview of the overall current and future market scenario. The Web Accessibility Assessment Tools report includes in-depth research on potential segments including product types, applications and end-users along with their contribution to the overall market size.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=252525

The Major Players Covered By Web Accessibility Assessment Tools Markets:

  • Google
  • silk tide
  • Site improvement
  • Deque
  • BoIA
  • DYNO Mapper
  • DubBot
  • Crown top
  • Monsido
  • Access level
  • UserWay Inc.

Market segmentation of automated drug delivery systems:

The Automated Drug Delivery Systems market report has categorized the market into segments comprising type of product and application. Each segment is evaluated based on share and growth rate. Meanwhile, analysts looked at potential areas that could prove rewarding for builders in the years to come. The regional analysis includes reliable forecast on value and volume, thereby helping market players to acquire in-depth insights into the entire industry.

Web Accessibility Assessment Tools Market Split By Type:

  • Automation Assessment Tools
  • Manual assessment tools

Web Accessibility Assessment Tools Market Split By Application:

  • Website owners
  • Website Developers
  • Sales teams

Based on geography: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina and Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa).

Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=252525

Scope of the Web Accessibility Assessment Tools Market Report

Report attribute Details
Market size available for years 2021 – 2028
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2028
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

Key questions answered in the report:

  • What is the growth potential of the web accessibility assessment tools markets?
  • Which product segment will take the lion’s share?
  • Which regional market will emerge as a precursor in the years to come?
  • Which application segment will grow at a sustained rate?
  • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
  • What are the main challenges that the global web accessibility assessment tools markets could face in the future?
  • Who are the leading companies in the global web accessibility assessment tools market?
  • What are the main trends that are positively impacting the growth of the market?
  • What are the growth strategies considered by the players to maintain their grip on the global Web Accessibility Assessment Tools market?

For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-web-accessibility-evaluation-tools-market-size-and-forecast/

The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Web Accessibility Assessment Tools market for each key company, and covers the breakdown data (production, consumption, revenue, and market share). market) by regions, type and applications. Historical breakdown data of Web accessibility assessment tools from 2016 to 2020 and forecast to 2021-2029.

About Us: Market Research Intelligence

Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

Website: –https://www.marketresearchintellect.com/


Source link

]]>
Data Foundation examines federal implementation of Evidence Act assessment provisions https://jackfeenyreviews.com/data-foundation-examines-federal-implementation-of-evidence-act-assessment-provisions/ Tue, 04 Jan 2022 21:43:08 +0000 https://jackfeenyreviews.com/data-foundation-examines-federal-implementation-of-evidence-act-assessment-provisions/ A Data Foundation investigation revealed progress in federal agencies’ implementation of the evaluation provisions of the Foundations for Evidence-Based Policymaking Act. The Data Foundation said 68% of federal evaluation officials surveyed said their agencies had published an evaluation policy and 41% of those polled said their organizations had developed an annual evaluation plan for the […]]]>

A Data Foundation investigation revealed progress in federal agencies’ implementation of the evaluation provisions of the Foundations for Evidence-Based Policymaking Act.

The Data Foundation said 68% of federal evaluation officials surveyed said their agencies had published an evaluation policy and 41% of those polled said their organizations had developed an annual evaluation plan for the fiscal year 2022.

Respondents reported high levels of collaboration with data officers, statistics officers and senior executives in writing agency learning programs, according to the Washington, DC-based nonprofit think tank.

The study showed that assessment officers are experienced and clear in their roles. Almost 90 percent of respondents said they had spent more than five years in the federal government, and at least half of them had served as an evaluation manager for more than five years. Seventy-one percent of respondents said they understood their role as an evaluation manager.

Seventy-five percent of those surveyed said they believed evaluation officials were “better able to respond to evaluation capacity and process issues codified in the evidence law at the time of the survey. that in 2018, before the adoption of the law on evidence ”, we read in the report. .

The study also found that the size of budgets and staff to support evaluation differs considerably from government to government, and that evaluation officers need additional support and resources to move the evaluation forward. implementation of the Evidence Act.

The report listed eight recommendations for advancing the evaluation function within the federal government, including the need for the Office of Management and Budget and agencies to seek funding flexibility and increased resources in budget request. of the president for the capacity to assess and appeal to senior agency executives. empower evaluation officers to conduct training and education initiatives on evaluation.

The Data Foundation interviewed federal evaluation officials between October 22 and November 15, in partnership with the American Evaluation Association. The complete contact list for the survey included 158 valid contacts. A total of 21 respondents responded to the survey, representing a response rate of 13%. While 32 contacts responded to at least part of the survey, showing a response rate of 20%.


Source link

]]>
PM Prayut approves panel to assess Section 112 cases https://jackfeenyreviews.com/pm-prayut-approves-panel-to-assess-section-112-cases/ Sun, 02 Jan 2022 19:45:31 +0000 https://jackfeenyreviews.com/pm-prayut-approves-panel-to-assess-section-112-cases/ As many protest and fight for the repeal or reform of Thailand’s harsh lese majesty laws – also known as Article 112 – PM Prayut Chan-o-cha has agreed to a plan proposed by the party pro-monarchy KLA to convene a panel to review all complaints filed before filing a complaint. The panel will be made […]]]>

As many protest and fight for the repeal or reform of Thailand’s harsh lese majesty laws – also known as Article 112 – PM Prayut Chan-o-cha has agreed to a plan proposed by the party pro-monarchy KLA to convene a panel to review all complaints filed before filing a complaint. The panel will be made up of experts who will assess any complaint filed with the police and decide whether it is worth pursuing or dropping it.

The idea was first brought up during a debate with a strong supporter of monarchical law reform within the Progressive Movement which took place on November 5. Thailand and the monarchy.

The proposal that won the Prime Minister’s backing would completely abandon the idea of ​​any sort of reform of Section 112 laws and instead send all charges to the special 7-person panel for assessment. Panel members would include a representative from the Royal Thai Police, the Supreme Court and the Attorney General’s office, as well as two political science experts and two other legal experts.

Under the current state of the law, any Thai person can file a Section 112 complaint against anyone they believe has done something against the monarchy of Thailand and the police are required to deal with the complaint. Rather, the new panel would consider any complaint brought against someone under Section 112 and if it finds the case to be without merit, the case should be dropped. If they find enough substance to prosecute the charge, then the case can be pursued by the police and the courts.

The general secretary of the KLA party that proposed the idea said they submitted it just 3 days later, on November 8, to Justice Minister Somsak Thepsuthin. He says they learned from the Justice Minister yesterday that Prime Minister Prayut approved their proposal, although it is not known when the plan will unfold and the panel will be selected.

SOURCE: Thai PBS World


Source link

]]>
Assessment of the latest treatment options for Covid-19 https://jackfeenyreviews.com/assessment-of-the-latest-treatment-options-for-covid-19/ Sat, 01 Jan 2022 03:09:56 +0000 https://jackfeenyreviews.com/assessment-of-the-latest-treatment-options-for-covid-19/ Female doctor doing a medical examination on an elderly woman at her home getty After two years of trying to eradicate Covid-19, the United States is currently experiencing the strongest outbreak of a pandemic to date. But there is good news: With 73 percent of the population vaccinated, hospitalization rates are dropping even as infection […]]]>

After two years of trying to eradicate Covid-19, the United States is currently experiencing the strongest outbreak of a pandemic to date. But there is good news: With 73 percent of the population vaccinated, hospitalization rates are dropping even as infection rates are rising. And those infected today actually have treatment options available to them; something that people infected a year ago couldn’t say.

Current treatment options

“There are now a number of important treatment options for ambulatory patients who develop Covid-19,” explained David Margolis, MD, MPH, head of infectious diseases at Brii Bio.

One of the first treatments available was monoclonal antibody treatments.

“[These treatments] specifically target the SARS-CoV-2 virus, preventing binding and attachment to human cells, dramatically reducing the risk of more serious disease, ”explained Margolis. “Three different monoclonal antibody therapies have been approved so far as part of the US EUA process.”

These antibody treatments require injections and infusions, usually occurring in a hospital setting. But the treatment itself can be completed in a matter of hours, with patients going home the same day.

“More recently, two oral treatment options have also demonstrated the ability to reduce progression to more serious disease, with clinical trials conducted in individuals starting treatment within 5 days of symptom onset,” said Margolis.

These two treatments include Paxlovid from Pfizer and Molnupiravir from Merck.

Pharmacist Ralph Pisano, RPh, said that due to Paxlovid’s success in preventing serious illness, “the US government has agreed to purchase over 10 million treatments for over $ 5 billion.”

Better yet, he said neither Paxlovid nor Molnupiravir have shown any risk of significant side effects so far, although the long-term effects have yet to be studied.

“Pfizer’s pill is an inhibitor of the SARS-CoV-2-3CL protease, a familiar mechanism, while Merck’s pill disrupts the virus’s ability to replicate,” Pisano explained. “Because of their convenience and effectiveness, the medicines from Merck and Pfizer have been compared to Tamiflu, the now ubiquitous influenza treatment.

Margolis added: “IV remdesivir, initially studied in hospitalized patients, has also shown benefits for ambulatory patients at high risk of progression to serious disease. “

The key, however, is to seek treatment early. As Margolis explained, “in patients with severe disease, only a few treatments have shown clinical benefit, including the use of IV steroids to reduce mortality and IV Remdesivir to limit the duration of the disease. certain individuals. “

Who should seek treatment?

So, if treatment options are most effective when continued early in the diagnosis, often before symptoms worsen, who should seek treatment when they recover that positive test?

Margolis said: “Treatment should be considered for any patient with symptomatic Covid-19 who has risk factors for progression to more serious disease. “

According to him, those with the highest risk factors include:

  • Individuals over 60 years old
  • Patients with other health problems, such as diabetes, asthma, or cancer
  • Patients with a history of smoking

Effectiveness of treatment

Patients may not remember to contact their doctor and seek treatment if they do not yet have severe symptoms. But these treatments have been shown to be effective in preventing serious illness, which is exactly why those most at risk should.

“In patients with mild to moderate symptoms, treatments such as monoclonal antibodies can be very effective in preventing progression to more serious disease,” explained Margolis, adding that the oral drug Paxlovid has been shown to reduce hospitalizations and 89% of deaths.

“These data suggest that ensuring patients have access to therapy can play a very important role in reducing the need for hospitalization or the progression to more serious illness,” he said. “It benefits both individuals and healthcare systems, which are under tremendous pressure in treating COVID-19 patients, especially now during this surge of omicron cases which is increasing in the United States and the United States. world. “

Pisano was also quick to tout the benefits of these treatments in combating the worst impacts of Covid-19.

“It’s hard to overstate how the expansion beyond vaccines with other methods of preventing Covid-19 hospitalizations will be a game-changer,” he said. “The treatments will also help ease the financial toll of the pandemic. Based on the tariff paid by the federal government, the price of Pfizer’s drug is approximately $ 500 per patient. Merck is even higher at $ 700-800. While this may seem high, it is a small fraction of the cost of hospitalization and therefore the overall savings to the healthcare system. “

Can children access these treatment options?

It’s one thing to be self-diagnosed with Covid-19, but for many parents the real concern is having their children diagnosed. This is why they may wonder what treatment options are available for their children, especially those with health conditions that present an additional risk factor.

“Many US FDA EUA-approved treatment options have been approved up to the age of 12, including monoclonal antibodies and Paxlovid, Pfizer’s new oral treatment,” said Margolis .

In fact, since December 3e, two antibody treatments have been approved for all pediatric patients.

“Parents of younger children who contract COVID-19, especially those with high-risk illnesses such as cancer or immunosuppression, should contact their health care provider to see if they may be eligible for an ongoing clinical trial, ”said Margolis.

As with everything related to Covid-19, we are learning more every day. This is why Margolis explained, “The data for various treatment options and the impact of different variants of this virus is changing rapidly, but there are a number of very effective treatment options that can help you or the limbs. of your family who may have contracted Covid-19. , including treatment options that may reduce your risk of needing hospitalization and developing serious illness or dying.

So, if you or a loved one tests positive for Covid-19, feel free to contact your family doctor to see what options may be available to you.

Vaccinated or not, the need for treatment can arise for all of us at some point. Because, as Pisano said, “groundbreaking cases have shown that vaccines alone are not enough to rule the human or financial cost of the pandemic. “

Still, he hopes the introduction of treatment options will help allay fears surrounding Covid-19 for good.

“2020 was the year of the shutdown,” he said. “2021 was the year of the vaccine. 2022 could be the year of Covid treatment. Hopefully 2023 is defined by something unrelated to the virus. “

It is a goal with which we can all step into the New Year.


Source link

]]>
Poor assessment of ex-MVP to blame for team struggles https://jackfeenyreviews.com/poor-assessment-of-ex-mvp-to-blame-for-team-struggles/ Thu, 30 Dec 2021 12:50:05 +0000 https://jackfeenyreviews.com/poor-assessment-of-ex-mvp-to-blame-for-team-struggles/ KEY POINTS Lakers management should be blamed for team woes, not Westbrook by sports scribe Westbrook coming into Lakers fold may have been misjudged by James and management Westbrook could be traded before NBA trade deadline, but move offers no assurance Despite his best efforts, Russell Westbrook’s patience appears to be running out as he […]]]>

KEY POINTS

  • Lakers management should be blamed for team woes, not Westbrook by sports scribe
  • Westbrook coming into Lakers fold may have been misjudged by James and management
  • Westbrook could be traded before NBA trade deadline, but move offers no assurance

Despite his best efforts, Russell Westbrook’s patience appears to be running out as he continues to struggle to prove he is a successful addition to the Los Angeles Lakers.

Being a former MVP, expectations were high when he was acquired by the Lakers in the offseason.

Los Angeles needed a third superstar, someone who could score and perform playmaking tasks.

On paper, everything looked perfect, although the thought of seeing how Westbrook might have less contact caught the pundits.

Therefore, the fit was seen as the next thing critics wanted to see, even though it was something that applied to all of the new faces on the Lakers roster.

But in the eyes of Forbes’ Morten Jensen, the fault should be blamed on Lakers management for the Westbrook deal.

Westbrook has had his moments with the Lakers although his stint this 2021-22 season has not started off on the right foot.

His numbers are a long way off and most felt the 33-year-old was not a good fit for the Lakers’ system.

Most criticize Westbrook for not adjusting to a new environment where he combines with not one but two legitimate superstars.

However, the nine-time All-Star believes he is doing well and that most choose to criticize his bad games rather than his good ones.

“The conversation has been a lot about how I play and what I do, but I think people expect me to be 25, 15 and 15,” Westbrook said in a report from the Launderer report. “This is not normal. Everyone should understand that it is not a normal thing that people do on a regular basis.”

Los Angeles Lakers goalie Russell Westbrook # 0 handles the ball against Memphis Grizzlies goalie Tyus Jones # 21 Photo: Getty Images | Justin ford

At this point in the NBA season, the Lakers’ performance has fallen short of expectations.

The NBA trade deadline is fast approaching and it’s unclear if Westbrook will be dealt with.

Should that happen, there’s no guarantee the Lakers will improve either, especially as stars like Anthony Davis are sidelined with injuries.



Source link

]]>
Ontario health officials assess new CDC guidelines on shortened COVID isolation https://jackfeenyreviews.com/ontario-health-officials-assess-new-cdc-guidelines-on-shortened-covid-isolation/ Tue, 28 Dec 2021 17:33:34 +0000 https://jackfeenyreviews.com/ontario-health-officials-assess-new-cdc-guidelines-on-shortened-covid-isolation/ Ontario health officials are reviewing new guidance from the U.S. Centers for Disease Control and Prevention on reducing isolation and quarantine times for COVID-19. Ontario’s Chief Medical Officer of Health Dr. Kieran Moore was scheduled to hold a media availability Tuesday afternoon to provide an update on contact tracing and COVID-19 testing in the province, […]]]>

Ontario health officials are reviewing new guidance from the U.S. Centers for Disease Control and Prevention on reducing isolation and quarantine times for COVID-19.

Ontario’s Chief Medical Officer of Health Dr. Kieran Moore was scheduled to hold a media availability Tuesday afternoon to provide an update on contact tracing and COVID-19 testing in the province, but its update has been postponed.

Read more:

CDC now recommends people isolated from COVID-19 for 5 days, up from 10

“In light of the recently updated guidance from the Centers for Disease Control and Prevention on reducing the recommended isolation and quarantine period, the Office of the Chief Medical Officer of Health and Public Health Ontario are weighing these guidelines against the evidence. specific to Ontario, ”said statement from Carly Luis, Director of Communications for Health Minister Christine Elliott, said.

Moore will now provide an update later this week.

The story continues under the ad

U.S. health officials on Monday reduced isolation restrictions for Americans who catch COVID-19 from 10 days to five days if they are no longer showing symptoms, and also shortened the time it takes to quarantine close contacts .

CDC officials said the guidelines are in line with growing evidence that people with coronavirus are most contagious in the two days before and three days after symptoms appear.

– With files from The Associated Press


Click to play video:







More provinces impose new COVID-19 restrictions amid Omicron soar


More provinces impose new COVID-19 restrictions amid Omicron soar

© 2021 Global News, a division of Corus Entertainment Inc.


Source link

]]>